logo
Mr. Gad Issues Definitive Proxy Statement for Upcoming Annual Meeting at Paragon

Mr. Gad Issues Definitive Proxy Statement for Upcoming Annual Meeting at Paragon

Urges Stockholders to Vote on the BLUE Proxy Card to Elect His Slate of Director Nominees Who are Committed to Prioritizing Stockholders' Interest, Restoring Confidence and Unlocking Value
NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Hesham 'Sham' Gad, who beneficially owns approximately 28.2% of the outstanding shares of common stock of Paragon Technologies, Inc. ('Paragon' or the 'Company') (OTC Pink:PGNT) and is Paragon's largest stockholder, announced that he has mailed his definitive proxy statement in connection with the Company's upcoming 2025 Annual Meeting of Stockholders and sent a letter to the Company's stockholders outlining why he believes significant change is needed in the boardroom for the Company to fulfill its potential.
The full text of the letter is set forth below:
Dear Fellow Paragon Stockholders:
I believe that stockholders would greatly benefit from significant changes to the composition of Board of Directors (the 'Board') of Paragon Technologies, Inc. ('Paragon' or the 'Company'). As the Company's largest stockholder and a loyal long-term investor and Board member, my interests are aligned with those of all Paragon stockholders. I believe there is significant value to be realized at Paragon. However, as the past few months have shown, I am deeply concerned that the majority of the incumbent Board has not demonstrated a commitment to acting in the best interests of stockholders and has failed to deploy an effective strategy at the Company. Unfortunately, the majority of the incumbent directors have spent the past year doing what failing boards so often do, rewriting history and burning through stockholder capital to entrench themselves.
Today, Paragon stands at a critical juncture-not because of external forces or market challenges, but because a group of entrenched directors are waging a deceptive and self-serving campaign to seize control of your company. They offer no strategy, no experience, and no track record-only distractions, distortion, and destruction.
This proxy contest is not about personalities-it's about performance, capital allocation, integrity, and the future of Paragon.
The Real Track Record - Built for Stockholders by Stockholders
During my 10-year tenure as CEO of Paragon from 2014 through August 2024, stockholders realized an 11% annualized return.
In 2017, when I assumed oversight of SI Systems, LLC ('SI Systems') and complete capital allocation of all of Paragon, stockholders realized approximately 30% annualized return through August 2024, when Weiser began his personal campaign against me and removed me as CEO.
During my time running SI Systems beginning in 2017, both SI Systems and Paragon have been radically transformed:
How was this capital allocated?
All of the above was achieved starting with a single business generating around $8 million in revenue and losing money. From that single business, Paragon is now generating over $100 million in revenues and significant profitability for shareholders. Most importantly these results were achieved without raising outside capital or taking on debt, and with minimal stockholder dilution - a hallmark of prudent, shareholder-centric, and disciplined capital allocation. Best of all, our shareholders had been rewarded with significant shareholder returns until Weiser and his hand-picked directors took control. However, I am optimistic that the shared culture we have created over many years will withstand the distracting rhetoric, and I hope the Company's faithful, long-term shareholders will soon see their continued commitment and investment guided by the right leadership.
These returns reflect real value-not speculation, not promises to deliver in the future.
With the right plan and right people in place, I am confident that Paragon can deliver meaningful long-term value to our stockholders, who are truly our partners. I urge you to protect and enhance the value of your investment by voting for my director nominees - David Duquette, Hesham M. Gad, James Kaufman, Elodie Leoni, and Ronell Rivera. Together, we can again make Paragon exceptional.
PLEASE VOTE YOUR BLUE PROXY CARD TODAY.
I look forward to continuing to engage transparently and collaboratively with my fellow stockholders and urge you to support my slate of uniquely qualified director candidates to help usher in a new era of growth and success at the Company.
Further information and resources in connection with my campaign for change, accountability and a stockholder-first culture at Paragon are available at www.saratogaproxy.com/PGNT. Thank you for your consideration.
Sincerely,
Sham Gad
For inquiries, please reach out to the address below:
[email protected]
Saratoga Proxy Consulting LLC
John Ferguson
(212) 257-1311/(888) 368-0379
[email protected]
SOURCE: Sham Gad
press release

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Bernstein Maintains a Market Perform Rating on Etsy (ETSY), Sets Price Target at $45
Bernstein Maintains a Market Perform Rating on Etsy (ETSY), Sets Price Target at $45

Yahoo

time19 minutes ago

  • Yahoo

Bernstein Maintains a Market Perform Rating on Etsy (ETSY), Sets Price Target at $45

Bernstein SocGen Group maintained a Market Perform rating on Etsy, Inc. (NASDAQ:ETSY) with a price target of $45 on June 5. The analysts observed that growing investor confidence and potential short covering led Etsy shares to climb 32% since last month. A young woman shopping for a vintage fashion item online. Bernstein analysts noted that the upward momentum in Etsy, Inc. (NASDAQ:ETSY) stock is due to stronger alternative data indicating a slowdown in the annual decline of Gross Merchandise Sales in May. This data demonstrates an optimistic outlook for Etsy's growth, particularly compared to its prior lower trading multiples. The stock has gained significant ground, rising 16.15% over the last week and 16.37% so far this year. Although the main driver of this upward swing in the stock remains unclear, the analysts commented that lower traffic for Temu, an Etsy competitor, in May could be a catalyst. They also said that possible changes in products listed at Etsy could be behind this positive trajectory. The report pointed to stronger credit card spending in May and a rise in monthly app usage for Etsy, Inc. (NASDAQ:ETSY), which coincided with Temu witnessing a 43% drop in active users year-over-year. Although the analysts acknowledged that their data might not perfectly match Etsy's reported Gross Merchandise Sales, the overall signals suggest things are moving in a positive direction. Etsy, Inc. (NASDAQ:ETSY) runs global online marketplaces that bring together buyers and sellers through its main platform, Etsy, as well as Reverb for musical instruments and Depop for fashion resale. While we acknowledge the potential of ETSY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. Read Next: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Confused by latest order? How to calculate if your Jackson County assessment is within limits
Confused by latest order? How to calculate if your Jackson County assessment is within limits

Yahoo

time3 hours ago

  • Yahoo

Confused by latest order? How to calculate if your Jackson County assessment is within limits

KANSAS CITY, Mo. — Jackson County assessments are showing up in homeowner's mailboxes. Some people may be surprised at the increase after a May order from the State Tax Commission. Some taxpayers may receive tax refunds in June: When payments could arrive That order capped increases in each assessment period at 15% and set 2022 as a starting point for this year's assessments after 2023 assessments were heavily contested. But determining your maximum 2025 assessment is a little bit more complicated than a single multiplication or division. Legislator Sean Smith and Preston Smith (no relation) have been helping homeowners with appeals since assessments skyrocketed in 2023. This week as they went out again they've been getting questions about what the latest State Tax Commission Order and 15% cap really means. 'People look at it and the first thing they see is, I thought it was only going to be a 15% increase and that was the perception. I've probably answered it online 100 times,' Preston Smith said. 'A lot of people are contacting me thinking they only do the 15 percent once, but you have to do it twice,' Legislator Sean Smith explained. To illustrate how it works with the latest rules using 2022 assessments as the starting point, consider a home with a $100,000 assessed value in 2022. To calculate the maximum assessed value in 2023 multiply $100,000 by 1.15 which is $115,000. But then you have to multiply by 115% again to determine the maximum value a home could be assessed at this year. In this example it would be $132,250. The two 15% increases end up yielding a maximum increase of 32.25% during the two assessment periods. 'I would really urge people to do the math themselves to check it, check and really verify,' Preston Smith said. To do that, however, you have to know your home's 2022 assessed value, which according to those who have received this year's assessments, isn't on this year's notices. You can find that historical information online at the Jackson County Parcel Viewer or Ascend Web. If your increase ends up beyond the allowances under the State order or if you simply don't agree with your value, you still can appeal. Appeals have to be filed by July 14. Download WDAF+ for Roku, Fire TV, Apple TV As for seniors, 40,000 are already enrolled in a new tax credit program freezing tax bills. The county says estimated savings are included on notices, but are subject to change. Both Sean and Preston Smith say they are pressing the Assessor's Office for complete assessment data in 2022, 2023 and 2025 to see how much home values increased, and how many of those increases equated to the maximum allowed if no new construction was done under the State Tax Commission Order without a physical inspection. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial

Yahoo

time5 hours ago

  • Yahoo

H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial

On June 4, analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Immix Biopharma, Inc. (NASDAQ:IMMX) with a price target of $7.00. The analyst based the rating on the promising interim results from the NEXICART-2 Phase 1/2 clinical trial of NXC-201, presented at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) in Chicago, Illinois. The trial assessed the efficacy of NXC-201 in patients with relapsed/refractory AL amyloidosis and delivered a 100% response rate, with a considerable portion attaining a complete hematologic response. The analyst reasoned that the absence of hematologic relapse or progression and the rapid mean time to response further highlight NXC-201's potential as a viable treatment. A doctor in a white coat discussing clinical trial results with a patient in an oncology practice. Burns also reasoned that NXC-201 appears to have a favorable safety profile, as no patients experienced severe cytokine release syndrome or neurotoxicity. While he highlighted the need for longer-term follow-up and the small sample size, the analyst stated that the interim results are promising when compared to existing treatments. This condition does not have FDA-approved agents, and there exists a fragmented treatment landscape post-frontline therapy, factors that suggest the notable market opportunity for NXC-201 and support the buy rating for Immix Biopharma, Inc. (NASDAQ:IMMX). Immix Biopharma, Inc. (NASDAQ:IMMX) is a biopharmaceutical company that develops therapies for inflammatory diseases and cancer. While we acknowledge the potential of IMMX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store